Immediate and long-term impact of the COVID-19 pandemic on cardiovascular clinical trials: considerations for study conduct and endpoint determination

Alexandra J. Lansky; Tayyab Shah; William Wijns; Giulio Stefanini; Andrew Farb; Aaron V. Kaplan; Bo Xu; Cody Pietras; Eric J. Velazquez; Patrick W. Serruys; Felix Mahfoud; Andreas Baumbach

doi:10.4244/eijv16i10a147

Related publications

Article2021

COVID-19: A Catalyst for Transforming Randomized Trials

Jennifer Lee, Jerri C. Price, William M. Jackson, Robert A. Whittington, John P A Ioannidis

Article2020

A Comprehensive Analysis of Clinical Trials in the COVID-19 Pandemic Era

Jinhee Lee, Han Wul Shin, Jun Young Lee, Jae Seok Kim, Jae Won Yang, Keum Hwa Lee, Andreas Kronbichler, Jae Il Shin

Article2023

Conducting CNS trials during a public health emergency – Lessons learned from the COVID-19 pandemic: A joint ISCTM/ECNP working group consensus paper

Kemi Olugemo, Dragana Bugarski‐Kirola, Gerard R. Dawson, Franco DiCesare, Dejan Stevanović, Janko Samardžić, Andreas Chatzittofis, Raeanne C. Moore, Joris C. Verster, Lais Bhering, Eduard Vieta

Article2024

Challenges in conducting efficacy trials for new COVID-19 vaccines in developed countries

Rafael Dal‐Ré, Emmanuel Bottieau, Odile Launay, Frits R. Rosendaal, Brigitte Schwarzer‐Daum

Clinical Trials

Article2021

The impact of the COVID-19 pandemic on an international rehabilitation study in MS: the CogEx experience

Anthony Feinstein, Maria Pia Amato, Giampaolo Brichetto, Jeremy Chataway, Nancy D. Chiaravalloti, Gary Cutter, Ulrik Dalgas, John DeLuca, Rachel Farrell, Peter Feys, Massimo Filippi, Jennifer Freeman, Matilde Inglese, Cecilia Meza, Rob Motl, Maria A. Rocca, Brian M. Sandroff, Amber Salter